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Thalassemia major (TM) is a congenital hemotlytic disorder caused by decreased production of globin chains. It is known that there is a hight
er than normal incidence of thromboembolic events in 
TM.1 Silent infarctions have also been documented.2,3 
Thromboembolic events occur at a significantly higher 
incidence statistically in the presence of other hypert
coagulability factors, and prophylactic antithrombotic 
therapy has been suggested in these patients.1,4 Several 
etiologic factors may play a role in the pathogenesis of 
the hypercoagulable state in thalassemia. We report a 
case of TM associated with a methylenetetrahydrofot
late reductase (MTHFR) mutation in which recurrent 
cerebral stroke was noted during follow up. 
CASE 
A 3tyeartold boy was admitted to our clinic with left 
hemiparesis. He was diagnosed with thalassemia major 
by hemoglobin electrophoresis at the age of 4 months, 
and had since been followed by the pediatric hematolt
ogy department with irregular hemotransfusions. He 
had 3 sisters and 3 brothers, and one of his brothers 
had thalassemia major. His parents had the thalassemia 
trait, and there was consanguinity between them. There 
was no family history of thromboembolic events. 
At the first admission, on physical and neurologit
cal examination, he had the typical facial appearance of 
thalassemia major and moderate hepatosplenomegaly. 
His consciousness was mildly depressed, and he had 
left hemiparesis. In the laboratory examination, his het
moglobin level was 4.5 g/L, the leukocyte count was 
calculated as 11.3×109/L, and the thrombocyte count 
was 153×109/L. Blood biochemistry and blood gas 
analysis were normal. A thrombophilic pattern, includt
ing antiphospholipid antibodies, lipoprotein(a), factor 
VIII, factor IX, antithrombin III, protein S levels, act
tivated protein C resistance, prothrombin 20210GtA, 
factor V Leiden, and MTHFR C677T mutations were 
unremarkable. However, protein C was 42% (normal, 
70%t130%), and a MTHFR 1298 heterozygous mut
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tation was found, but the level of homocysteine could 
not be measured. The protein C level was in the normal 
range 4 months after the first stroke. Other thrombot
philic factors like the haplotype HR2 (H1299R) in 
the gene encoding factor V (A4070G), mutations/
polymorphisms in factor II (FII20210A) and fibrinot
gen genes (beta fibrinogen gene Gt455tA), C1565T 
GpIIb/IIIa, or 4HPVRtfactor VII could not be evalut
ated. The genotype of the patient also could not be evalt
uated. His brother with thalassemia was also examined 
for the same thrombophilic factors, but no abnormality 
was found.
The echocardiographic examination was normal. On 
a cerebral MRI there were acute ischemic lesions in the 
right frontal and parietal lobes. He was put on subcut
taneous nadroparin and oral folate treatment for stroke 
prophylaxis. Hemiparesis was improved in one month. 
After 2 months from the left hemiparesis attack, he 
had undergone splenectomy because of hypersplenism. 
After splenectomy, his hemoglobin level was 9.2 g/L, 
the leucocyte count was calculated as 18.0×109/L, and 
the platelet count was 400×109/L.
At the age of 4.5 years he was admitted to our host
pital with focal seizures and right hemiparesis. He used 
no medications other than folate and subcutaneous nat
droparin. His physical and neurological examinations 
were normal, except for right hemiparesis. On cerebral 
CT, in addition to old lesions, acute ischemic lesions 
were found in the left temporoparietooccipital regions 
(Figure 1). 
DISCUSSION
There have been several reports of thromboembolic 
complications associated with thalassemia major.1t4 
Thromboembolic events are also found in patients with 
Sbtthalassemia, thalassemia intermedia (TI), btthalt
assemia/hemoglobin E and btthalassemia.5,6 All these 
reports were from patients who were not given regular 
transfusions, or after splenectomy, or had some addit
tional hypercoagulability factors. In one study, the prevt
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alence of thromboembolic events was 3.3% with btTM 
and 16.2% with btTI, although 15.3% of these patients 
had predisposing congenital or acquired factors cont
tributing to the hypercoagulability.7 Borgna Pignatti et 
al8 found that the prevalence of thromboembolic events 
was 3.95% and 9.61% in TM and TI, respectively. TI is 
associated with a higher incidence of thrombosis comt
pared with TM, particularly in patients who are splet
nectomised.9
There is great variation in localization of stroke. 
Because of the higher incidence of cerebral stroke in TM, 
patients should be closely monitored. Asymptomatic 
brain damage has also been reported with thalassemia.3 
Cerebral damage is inversely correlated with hemoglot
bin levels and increases with age.
There are several hemostatic changes in patients 
with thalassemia. The results from studies in patients 
show that in addition to high platelet counts in splet
nectomized patients, chronic platelet activation is prest
ent in patients having thalassemia.10,11 The detection of 
elevated levels of endothelial adhesion proteins in the 
serum and plasma of patients suggests that endothelial 
activation or injury may be a feature of the disorder.12 
In addition, monocyte activation and elevated granut
locyte phagocytic function may also play a significant 
role in the thrombosis.13 Several authors have reported 
profound changes in the levels of coagulation factors, 
coagulation factor inhibitors, and components of the 
fibrinolytic system. Low levels of protein C, and free 
protein S were reported in thalassemic patients.5,14 Red 
blood cells from thalassemic patients also demonstrate 
enhanced cohesiveness, which may contribute to the 
hypercoagulable state.15 In addition to these pathot
genic mechanisms, irontmediated oxidative stress may 
be an important determinant of stroke in thalassemic 
patients receiving blood transfusions on a chronic basis. 
Ionic iron catalyses the generation of reactive oxygen 
species via the Fenton reaction and may exacerbate the 
vascular damage caused by the ischemia. It has been 
thought that astrocytic and neuronal mitochondria are 
vulnerable to oxidative stress, and this is closely corret
lated with iron availability. This pathogenic mechanism 
predisposes the patient to the elevated risk of iron accut
mulation, although iron chelation therapy is routinely 
administered to these patients.16 Damage to endothelial 
cells due to an ongoing inflammatory state, which can 
be improved by iron chelation therapy, may also be a 
contributing factor.9 Besides these hematostatic changt
es, some systemic problems in these patients, such as 
the presence of cardiac arrhythmias and a status liver 
iron overload and liver function may contribute to the 
hypercoagulopathy. 
Our patient was diagnosed with thalassemia major 
at the age of 4 months, and has since been followed with 
irregular erythrocyte transfusion. Because of multiple 
stroke risk factors such as heterozygous MTHFR mut
tation, a thromboembolic event did recur, even though 
prophylactic therapy was regular. It is known that 
MTHFR mutations cause hyperhomocysteinemia. 
High levels of homocysteine induce desquamation of 
the vascular endothelium, which then causes platelet 
activation. In a baboon model,17 continuous infusion of 
homocysteine resulted in patchy loss of vascular endot
thelium, and endothelial cells could be demonstrated 
circulating in the peripheral blood. Actual platelet funct
tion tests were normal in both patients and animals; the 
platelet destruction was shown to be secondary to the 
toxic effects of homocysteine on platelets. Furthermore, 
platelet destruction could be prevented by dipyridamt
ole, a drug that decreases platelet aggregation.17,18 As 
homocysteine levels in our patient were not evalut
ated, pathogenetic correlation of MTHFR mutation 
to thrombosis cannot be established. We thought that 
our patient had recurrent stroke despite treatment with 
nadroparin, because of the pathogenic changes of thalt
assemia major plus probable endovascular damage due 
to MTHFR mutation. Splenectomy also increased the 
risk of thrombosis and caused a second stroke attack. 
Thalassemia major patients who develop an acute 
thrombotic event (also patients with subclinical thromt
bosis) should be considered for prolonged antithromt
botic therapy, as should any patient with thrombophilt
ia, in view of their profound hemostatic anomalies. It is 
noteworthy that some thalassemic patients responded 
to treatment with platelet inhibitor drugs (aspirin and 
Figure 1. Cerebral computed tomography shows ischemic lesions 
in the left temporoparietooccipital regions, in addition to old 
lesions in the right hemisphere.
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dipyridamole) with a rise in their arterial oxygen cont
tent.1 Aspirin is the prototypical antiplatelet drug, ext
erting its antithrombotic action by irreversibly inactivatt
ing (by acetylation) the cyclooxygenase (COX) activity 
of platelet prostaglandin H synthaset1 (COXt1) and 
prostaglandin H syntaset2 (COXt2). Lower aspirin 
doses also inhibit vascular endothelial cell prostacyclin 
production to a lesser extent. Dipyridamole, used alone 
or in combination with aspirin, elevates intraplatelet 
cAMP by inhibition of cAMP phosphodiesterase, or 
by stimulation of adenylate cyclase activity, resulting 
in inhibition of platelet activation.19,20 Unfractionated 
heparin is also used in the prophylaxis and treatment 
of thrombosis. This drug primarily inhibits factor Xa 
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and has a lesser effect on inhibition of thrombin. Lowt
moleculartweight heparin, like nadroparin, has some 
advantages over unfractionated heparin in that it may 
be given subcutaneously, once or twice daily in dosages 
based solely on body weight, and without the need for 
laboratory monitoring.20
 In conclusion, stroke must always be kept in mind 
as a complication in TM, especially in patients that 
have additional thrombophilic risk factors. The stroke 
incidence is particularly increased in association with 
other hypercoagulable factors. Prolonged prophylactic 
antithrombotic therapy has been suggested in these pat
tients, particularly for those who have additional risk 
factors. 
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